Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Bioventus Inc. (BVS)

Bioventus Q3 revenue rises 3% to $142.4 million; net income up to $6.0 million

Positive Impact 4 of 5 earnings Written later

Bioventus reported third-quarter 2026 revenue of $142.4 million, up 3%, and net income attributable to the company of $6.0 million, up from $3.2 million a year earlier. The company reaffirmed its 2026 adjusted EPS guidance of $0.75 to $0.79 per diluted share and updated net sales guidance to $590 million to $595 million, while continuing to review potential strategic alternatives that followed an unsolicited acquisition proposal.

Key points

  • Q3 2026 revenue of $142.4 million rose 3%, led by Pain Treatments, which grew 6.2% to $71.3 million
  • GAAP diluted EPS was $0.08 versus $0.05 a year earlier; non-GAAP diluted EPS was $0.17 versus $0.15
  • 2026 guidance: adjusted EPS of $0.75 to $0.79 reaffirmed; net sales of $590 million to $595 million
  • Company continues to review potential strategic alternatives; cash from operations was $20.7 million in Q3

The filing

CompanyBioventus Inc. (BVS)
Form8-K, current report
Filed with the SECNov 2, 2026, 4:12 PM ET
Accession number0001665988-26-000050

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.